theliatinib
Phase 1- Indications
- Non-small cell lung cancer
Company intelligence / Profile preview
Hutchison
Shanghai, Shanghai, Chinahutchisonschool.org ↗
- Ownership
- Private
- Employees
- ~1970
- Development stage
- Phase 1
01
Overview
HUTCHMED has received FDA approval for fruquintinib for metastatic colorectal cancer in the US. In China, they received approval for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) to treat metastatic EGFR mutation-positive NSCLC with MET amplification. They completed enrollment of Phase II trial of fanregratinib for intrahepatic cholangiocarcinoma patients with FGFR2 fusion/rearrangement in March 2025.
- Therapeutic areas
- OncologyImmunologyGastroenterology
- Modalities
- Small moleculesantibody drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on Hutchison.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hutchison.